Skip to main navigation Skip to search Skip to main content

Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study

  • Michael Wang
  • , Javier Munoz
  • , Andre Goy
  • , Frederick Locke
  • , Caron A. Jacobson
  • , Brian T. Hill
  • , John M. Timmerman
  • , Houston Holmes
  • , Samantha Jaglowski
  • , Ian W. Flinn
  • , Peter A. Mcsweeney
  • , David B. Miklos
  • , John M. Pagel
  • , Marie José Kersten
  • , Krimo Bouabdallah
  • , Rashmi Khanal
  • , Roch Houot
  • , Amer Beitinjaneh
  • , Weimin Peng
  • , Xiang Fang
    • Rhine R. Shen, Rubina Siddigi, Ioana Kloos, Patrick M. Reagan
  • University of Texas MD Anderson Cancer Center
  • Banner Health
  • Rutgers - The State University of New Jersey, Newark
  • John Theurer Cancer Center
  • University of South Florida
  • Moffitt Cancer Center
  • Dana-Farber Cancer Institute
  • Cleveland Clinic Foundation
  • Case Western Reserve University
  • University of California at Los Angeles
  • Texas Oncology
  • Ohio State University
  • Sarah Cannon Research Institute
  • Colorado Blood Cancer Institute
  • Stanford University
  • Swedish Medical Center
  • Swedish Cancer Center
  • University of Amsterdam
  • Bordeaux University Hospital
  • Université de Rennes
  • CHU de Rennes
  • University of Miami
  • Kite, a Gilead Company
  • Kite Pharma
  • University of Rochester

Research output: Contribution to journal › Article › peer-review

317 Scopus citations

Search results